See more : Frasers Group plc (SDIPF) Income Statement Analysis – Financial Results
Complete financial analysis of RxSight, Inc. (RXST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of RxSight, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
- Hunya Foods Co., Ltd. (1236.TW) Income Statement Analysis – Financial Results
- TVS Supply Chain Solutions Limited (TVSSCS.NS) Income Statement Analysis – Financial Results
- Ichitan Group Public Company Limited (ICHI-R.BK) Income Statement Analysis – Financial Results
- Sunniva Inc. (SNN.CN) Income Statement Analysis – Financial Results
- PT Indosat Ooredoo Hutchison Tbk (PTITF) Income Statement Analysis – Financial Results
RxSight, Inc. (RXST)
About RxSight, Inc.
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 89.08M | 49.01M | 22.59M | 14.68M | 2.24M |
| Cost of Revenue | 35.31M | 27.68M | 18.08M | 12.97M | 4.06M |
| Gross Profit | 53.77M | 21.33M | 4.52M | 1.71M | -1.82M |
| Gross Profit Ratio | 60.36% | 43.52% | 19.99% | 11.62% | -81.17% |
| Research & Development | 29.05M | 25.98M | 24.50M | 21.93M | 29.57M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 74.80M | 58.67M | 32.81M | 15.18M | 15.20M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 103.85M | 84.65M | 57.30M | 37.11M | 44.77M |
| Cost & Expenses | 139.16M | 112.32M | 75.38M | 50.08M | 48.83M |
| Interest Income | 6.57M | 1.52M | 54.00K | 543.00K | 2.31M |
| Interest Expense | 3.31M | 4.95M | 3.68M | 510.00K | 26.00K |
| Depreciation & Amortization | 4.24M | 4.02M | 3.99M | 4.01M | 3.93M |
| EBITDA | -41.04M | -57.78M | -41.01M | 32.15M | 130.20M |
| EBITDA Ratio | -46.07% | -126.11% | -233.40% | -210.18% | -1,800.71% |
| Operating Income | -50.09M | -63.32M | -52.79M | -35.41M | -46.07M |
| Operating Income Ratio | -56.23% | -129.21% | -233.64% | -241.21% | -2,055.78% |
| Total Other Income/Expenses | 1.50M | -3.43M | 4.11M | 63.04M | 172.31M |
| Income Before Tax | -48.59M | -66.75M | -48.68M | 27.63M | 126.24M |
| Income Before Tax Ratio | -54.55% | -136.20% | -215.46% | 188.25% | 5,633.38% |
| Income Tax Expense | 20.00K | 9.00K | 8.00K | 57.00K | 24.00K |
| Net Income | -48.61M | -66.76M | -48.69M | 27.58M | 126.22M |
| Net Income Ratio | -54.57% | -136.22% | -215.50% | 187.87% | 5,632.31% |
| EPS | -1.41 | -2.41 | -1.78 | 0.12 | 0.95 |
| EPS Diluted | -1.41 | -2.41 | -1.78 | 0.12 | 0.95 |
| Weighted Avg Shares Out | 34.46M | 27.66M | 27.37M | 27.62M | 27.62M |
| Weighted Avg Shares Out (Dil) | 34.46M | 27.66M | 27.37M | 27.62M | 27.62M |
RxSight, Inc. (RXST) Q1 2024 Earnings Call Transcript
RxSight, Inc. Reports First Quarter 2024 Financial Results
RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024
RxSight Announces Commercial Launch of its Newest Light Adjustable Lens™, the LAL+™, and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting
RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference
RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference
RxSight, Inc. (RXST) Q4 2023 Earnings Call Transcript
RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
3 Stocks to Buy BEFORE They Become Household Names
Source: https://incomestatements.info
Category: Stock Reports